ストックスクリーナーアプリを入手
14.83
0.41%
0.227
Dyne Therapeutics Inc (DYN) 最新ニュース
Dyne Therapeutics, Inc. $DYN Shares Acquired by Vanguard Group Inc. - MarketBeat
Morgan Stanley Maintains 'Overweight' on DYN but Lowers Price Ta - GuruFocus
Dyne Therapeutics, Inc. (DYN) Stock Analysis: A Potential 142% Upside in the Biotech Arena - DirectorsTalk Interviews
Chardan Capital Maintains Buy Rating on Dyne Therapeutics (DYN) - GuruFocus
HC Wainwright & Co. Lowers Price Target for Dyne Therapeutics (D - GuruFocus
Decoding Dyne Therapeutics Inc (DYN): A Strategic SWOT Insight - GuruFocus
DYN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Overweight Maintained for Dyne Therapeutics (DYN) by Morgan Stanley March 2026 - Meyka
Raymond James reiterates Dyne Therapeutics stock rating on FDA pathway By Investing.com - Investing.com Canada
Dyne Therapeutics (NASDAQ:DYN) Shares Down 6.6% After Earnings Miss - MarketBeat
Morgan Stanley cuts Dyne Therapeutics stock price target on model update - Investing.com Canada
Dyne’s Larger 2025 Loss And New Shelf Registration Might Change The Case For Investing In Dyne Therapeutics (DYN) - simplywall.st
Dyne Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Dyne Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Dyne Therapeutics Posts Wider Loss In Q4 - Nasdaq
Dyne Therapeutics (DYN) Beats Q4 EPS Expectations - GuruFocus
Dyne Therapeutics Q4 Net Loss Narrows - marketscreener.com
Dyne Therapeutics (DYN) Approaches Key Transformation Phase - GuruFocus
DYNE THERAPEUTICS ($DYN) Releases Q4 2025 Earnings - Quiver Quantitative
Dyne Therapeutics (NASDAQ:DYN) Posts Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Dyne Therapeutics (NASDAQ: DYN) pairs 2025 loss with pivotal DMD and DM1 milestones - Stock Titan
Dyne Therapeutics eyes 2027 Duchenne drug launch, backed by $1.1B cash - Stock Titan
Dyne Therapeutics 2025 10-K: $0 Revenue, Net Loss $446.2M - TradingView
Dyne Therapeutics (NASDAQ: DYN) advances FORCE-based neuromuscular pipeline - Stock Titan
DYNDyne Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Oppenheimer Upgrades Dyne Ahead of Avidity's Upcoming Trial Results - Intellectia AI
Dyne Therapeutics, Inc. $DYN Holdings Raised by JPMorgan Chase & Co. - MarketBeat
DYN SEC FilingsDyne Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Sarepta CEO To Jump Ship After 'Tumultuous' Year - Benzinga
Dyne Announces Positive Results from DELIVER Trial for DMD at MDA Conference - Intellectia AI
Dyne Therapeutics earnings ahead: DMD filing timeline in focus - Investing.com Australia
Dyne Therapeutics to Participate in Upcoming Investor Conferences - Investing News Network
Biotech Dyne Therapeutics heads to three March investor conferences - Stock Titan
Dyne Therapeutics (DYN) Stock Analysis: Exploring a 153% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Price-Driven Insight from (DYN) for Rule-Based Strategy - Stock Traders Daily
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference - Sahm
Dyne Therapeutics (DYN) to Showcase Key Developments at 2026 MDA Conference - GuruFocus
Dyne Therapeutics to Showcase Positive Results from DELIVER Trial and Phase 3 Trial Design at 2026 MDA Clinical & Scientific Conference - Quiver Quantitative
New heart-lung data in rare muscle diseases: inside Dyne’s 2026 trial push - Stock Titan
Aberdeen Group plc Purchases 72,770 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Aug PostEarnings: Is Dyne Therapeutics Inc a turnaround storyBreakout Watch & Entry Point Confirmation Signals - baoquankhu1.vn
Dyne Therapeutics (DYN) to Release Earnings on Thursday - MarketBeat
Bullish Analyst Opinion on Dyne (DYNE) Follows Rare Disease Drug Progress in Japan - Finviz
VIX Spike: What is Dyne Therapeutics Incs 5 year growth outlookIPO Watch & Weekly Sector Rotation Insights - baoquankhu1.vn
Dyne Therapeutics, Inc. (DYN) Stock Analysis: Exploring a 151% Upside Potential in Biotech - DirectorsTalk Interviews
Weekly Trades: Can Dyne Therapeutics Inc disrupt its industry2025 Bull vs Bear & Weekly High Return Forecasts - baoquankhu1.vn
Dyne Therapeutics (DYN) Attains Orphan Drug Designation From Japanese Ministry - Finviz
Dyne Therapeutics announces $300M proposed public offering - MSN
Can Dyne Therapeutics Inc. disrupt its industryWeekly Risk Summary & Daily Profit Focused Stock Screening - mfd.ru
Earnings Risk: Is Dyne Therapeutics Inc gaining market shareJuly 2025 Movers & Verified Momentum Stock Watchlist - baoquankhu1.vn
What is Dyne Therapeutics Inc. s 5 year growth outlookChart Signals & Verified Swing Trading Watchlists - mfd.ru
Facioscapulohumeral Muscular Dystrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart.com
Facioscapulohumeral Muscular Dystrophy Market: High-Growth - openPR.com
(DYN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Will Dyne Therapeutics Inc. benefit from current market trendsLong Setup & Daily Technical Forecast Reports - mfd.ru
Candriam S.C.A. Has $10.55 Million Stock Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics, Inc. (DYN) Stock Analysis: Unveiling A 130% Potential Upside - DirectorsTalk Interviews
Facioscapulohumeral Muscular Dystrophy Pipeline 2025: Key - openPR.com
Facioscapulohumeral Muscular Dystrophy Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Fulcrum Therapeutics, Dyne Therapeutics, GSK, Roche, Facio Therapies - Barchart.com
0.14%
0.19%
大文字化:
|
ボリューム (24 時間):